Results 71 to 80 of about 4,898 (191)
Guidelines for Essential Trauma Care: Second Edition (2026)
World Journal of Surgery, Volume 50, Issue 6, Page 1409-1450, June 2026.Injury is a major cause of death and disability globally, with the highest burden in low‐ and middle‐income countries (LMICs). Strengthening the organization and planning for trauma care (care of the injured) can improve care and lower mortality. In 2004, the International Association for Trauma Surgery and Intensive Care (IATSIC) and the World Health ...
Charles Mock +41 more
wiley +1 more source
Kineochelins—A New Group of Siderophores From an Antarctic Bacterium
Microbial Biotechnology, Volume 19, Issue 6, June 2026.Genome‐guided analysis of an Antarctic Actinokineospora strain led to the discovery of kineochelins, a new group of siderophores involved in iron sequestration and microbial competition. Kineochelin production inhibits co‐occurring bacteria and clinically relevant yeasts, highlighting Antarctic microorganisms as promising sources of bioactive natural ...
Stanislava Kralova +12 more
wiley +1 more source
mSystems, 2023 Acinetobacter baumannii has become one of the most challenging pathogens in many countries with limited treatment options available. Cefiderocol, a novel siderophore-conjugated cephalosporin, shows potent in vitro activity against A. baumannii, including
Xiaochen Liu +10 more
doaj +1 more source
Target-site cefiderocol pharmacokinetics in soft tissues of healthy volunteers [PDF]
Background: Cefiderocol may potentially be used to treat skin and soft tissue infections (SSTIs). However, the pharmacokinetics of cefiderocol in human soft tissues have not yet been determined.
Coen van Hasselt, J. G. +12 more
core +1 more source
FEBS Open Bio, Volume 16, Issue 4, Page 751-765, April 2026.KHS‐Cnd peptide is able to impair biofilm formation and disaggregate mature biofilms in Acinetobacter baumannii clinical isolates. Differences in extracellular metabolites reflect changes in biofilm metabolism due to KHS‐Cnd treatment. Among the differentially represented extracellular metabolites upon KHS‐Cnd treatment, the significantly altered ...
Fernando Porcelli +9 more
wiley +1 more source
Cefiderocol in Difficult-to-Treat Nf-GNB in ICU Settings [PDF]
Background The efficacy and safety of cefiderocol in ICU patients with difficult-to-treat resistance (DTR) non-fermenting Gram-negative bacteria (Nf-GNB) are not as well-established.
Jean Christophe Richard +23 more
core +1 more source
Clinical Case Reports, Volume 14, Issue 4, April 2026.ABSTRACT S. maltophilia is a multidrug‐resistant nosocomial pathogen that poses significant challenges in CKD patients. Antibiotic selection in CKD is complicated by nephrotoxicity concerns and limited clinical data. Combination therapy and novel agents like cefiderocol and CZA‐ATM are emerging alternatives but require further validation.
Joydip Chowdhury +4 more
wiley +1 more source
Commercially available tests for determining cefiderocol susceptibility display variable performance in the Achromobacter genus [PDF]
International audienceBackground : Cefiderocol is a siderophore-conjugated cephalosporin increasingly used in the management of Achromobacter infections. Testing for cefiderocol susceptibility is challenging with distinct recommendations depending on the
Sorlin, Pauline +6 more
core +1 more source
Clinical Pharmacology &Therapeutics, Volume 119, Issue 4, Page 838-845, April 2026.The FDA published guidance on assessing pharmacokinetics (PK) in participants with impaired renal function in 2024. The IQ CPLG Organ Impairment Working Group summarized the industry’s perspective on this guidance by highlighting a few key updates in the 2024 guidance, including: (1) the recommendation of using estimated glomerular filtration rate ...
Yan Jin +13 more
wiley +1 more source
In Vitro Antibacterial Properties of Cefiderocol, a Novel Siderophore Cephalosporin, against Gram-Negative Bacteria [PDF]
, 2018 Cefiderocol (CFDC; S-649266), a novel parenteral siderophore cephalosporin conjugated with a catechol moiety, has a characteristic antibacterial spectrum with a potent activity against a broad range of aerobic Gram-negative bacterial species, including ...
Masakatsu Tsuji +12 more
core +1 more source